We are live on ! Find out more
ORKA

Oruka Therapeutics
ORKA

71 hedge funds and large institutions have $326M invested in Oruka Therapeutics in 2025 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 28 increasing their positions, 12 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 12

60% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 10

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

8% more funds holding

Funds holding: 66 → 71 (+5)

3.81% less ownership

Funds ownership: 88.68% → 84.87% (-3.8%)

46% less capital invested

Capital invested by funds: $607M → $326M (-$281M)

Holders
71
Holders Change
+5
Holders Change %
+7.58%
% of All Funds
0.95%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.05%
New
16
Increased
28
Reduced
12
Closed
10
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
+$2K

Top Buyers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
+$10.8M
2
DTC
Deep Track Capital
Connecticut
+$8.66M
3
Blackstone Inc
Blackstone Inc
New York
+$6.78M
4
PCH
Polar Capital Holdings
United Kingdom
+$6.24M
5
B
Braidwell
Connecticut
+$5.3M

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$16.4M
2
PA
Perceptive Advisors
New York
-$16.4M
3
PBA
Paradigm Biocapital Advisors
New York
-$15.9M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$11.4M
5
DCM
Driehaus Capital Management
Illinois
-$5.99M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$2.51M +$3.05M +244,199 New
IC
27
Ikarian Capital
Texas
$1.8M +$2.18M +175,000 New
ACM
28
ADAR1 Capital Management
Texas
$1.36M +$1.66M +132,780 New
CS
29
Candriam SCA
Luxembourg
$1.2M +$1.46M +116,698 New
Wellington Management Group
30
Wellington Management Group
Massachusetts
$898K -$94.6K -7,588 -8%
State Street
31
State Street
Massachusetts
$889K +$769K +61,658 +246%
Barclays
32
Barclays
United Kingdom
$773K +$9.35K +750 +1%
KCM
33
Kennedy Capital Management
Missouri
$675K +$65.5K +5,255 +9%
Northern Trust
34
Northern Trust
Illinois
$611K -$55.6K -4,459 -7%
Toronto Dominion Bank
35
Toronto Dominion Bank
Ontario, Canada
$598K – – –
BGI
36
B Group Inc
Texas
$597K +$477K +38,215 +191%
Millennium Management
37
Millennium Management
New York
$555K +$297K +23,821 +79%
BFM
38
Boothbay Fund Management
New York
$550K +$669K +53,615 New
Qube Research & Technologies (QRT)
39
Qube Research & Technologies (QRT)
United Kingdom
$534K -$1.25M -100,056 -66%
HF
40
HRT Financial
New York
$477K +$580K +46,511 New
TD Asset Management
41
TD Asset Management
Ontario, Canada
$471K -$614K -49,200 -52%
OAC
42
OMERS Administration Corp
Ontario, Canada
$461K +$313K +25,100 +127%
Manulife (Manufacturers Life Insurance)
43
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$440K +$7.75K +621 +1%
WAM
44
Weiss Asset Management
Massachusetts
$410K – – –
ECM
45
ExodusPoint Capital Management
New York
$368K +$448K +35,912 New
Renaissance Technologies
46
Renaissance Technologies
New York
$367K +$447K +35,800 New
UBS Group
47
UBS Group
Switzerland
$348K +$109K +8,721 +35%
OQS
48
Occudo Quantitative Strategies
Florida
$310K +$309K +24,804 New
Man Group
49
Man Group
United Kingdom
$301K +$366K +29,365 New
Squarepoint
50
Squarepoint
New York
$226K +$123K +9,847 +81%
1
2
3 4

ORKA Hedge Fund Activity: Q1 2025 in Review

71 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q1 2025, worth a combined $326M — down 46% from $607M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new ORKA positions and 10 closed out — a net gain of 6 holders — while 28 added to existing stakes and 12 trimmed.

The largest buyer was VR Adviser, adding an estimated $10.8M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $16.4M sold.

  • 71 institutional investors held Oruka Therapeutics (ORKA) as of Q1 2025, up from 66 in Q4 2024.
  • Funds reported $326M of Oruka Therapeutics stock for Q1 2025, down 46% quarter-over-quarter.
  • 16 funds opened new Oruka Therapeutics positions in Q1 2025 and 10 closed out, a net change of +6 holders.
  • The largest Oruka Therapeutics buyer in Q1 2025 was VR Adviser, an estimated $10.8M added.
  • The largest Oruka Therapeutics seller in Q1 2025 was Janus Henderson Group, an estimated $16.4M sold.

Based on aggregated 13F filings for Q1 2025.